Population‐Based Study on the Coexistence of Metabolic Dysfunction‐Associated Steatotic Liver Disease and Chronic Kidney Disease

MASLD(+)/CKD(+) phenotype increases the risk of cardiometabolic multimorbidity and independently predicts mortality. Mortality risk increased progressively in individuals with both advanced hepatic fibrosis and CKD.